Capital World Investors Has $86.37 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Capital World Investors lessened its stake in Kenvue Inc. (NYSE:KVUE) by 59.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,045,288 shares of the company’s stock after selling 5,963,626 shares during the quarter. Capital World Investors’ holdings in Kenvue were worth $86,367,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Bard Financial Services Inc. lifted its stake in Kenvue by 5.7% in the 3rd quarter. Bard Financial Services Inc. now owns 106,790 shares of the company’s stock valued at $2,470,000 after acquiring an additional 5,750 shares in the last quarter. Boyar Asset Management Inc. boosted its holdings in Kenvue by 7.2% during the third quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company’s stock worth $675,000 after purchasing an additional 1,948 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Kenvue in the third quarter valued at $1,057,000. Tidal Investments LLC increased its stake in Kenvue by 9.9% in the 3rd quarter. Tidal Investments LLC now owns 131,128 shares of the company’s stock valued at $3,033,000 after buying an additional 11,849 shares during the last quarter. Finally, Oddo BHF Asset Management Sas bought a new stake in Kenvue during the 3rd quarter worth about $1,570,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Barclays dropped their target price on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, April 14th. Canaccord Genuity Group boosted their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Evercore ISI assumed coverage on shares of Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. Finally, Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $24.42.

Kenvue Stock Down 4.7 %

KVUE opened at $22.29 on Tuesday. The stock has a fifty day moving average of $22.93 and a 200-day moving average of $22.41. The company has a market capitalization of $42.77 billion, a P/E ratio of 42.06, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.68%. The ex-dividend date is Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.